Is Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination or Nirsevimab Prophylaxis cost-effective for preventing RSV-associated disease in Japanese infants?
Japanese infants
Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination (RSVpreF) and Nirsevimab Prophylaxis
Cost-effectiveness (Quality-Adjusted Life Years / QALY)
Seasonal RSVpreF vaccination is a cost-effective strategy for preventing RSV-associated disease in Japanese infants at a threshold of US$33,333 per QALY.
Only seasonal RSVpreF strategy is cost-effective under the JPY5 000 000/US33 333 per QALY willingness-to-pay threshold.
Building similarity graph...
Analyzing shared references across papers
Loading...
Shu-Ling Hoshi
Xerxes Seposo
Masahide Kondo
Value in Health
Hokkaido University
University of Tsukuba
Tsukuba University of Technology
Building similarity graph...
Analyzing shared references across papers
Loading...
Hoshi et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69a76663badf0bb9e87dcd07 — DOI: https://doi.org/10.1016/j.jval.2026.01.010